Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS
Erin Sheffels, Robert L. Kortum
Abstract
In RTK/RAS-mutated cancers, therapeutic resistance is driven by rebound activation of multiple RTKs; broad inhibition of RTK signaling can potentially delay therapeutic resistance for a majority of patients. A new SOS1 inhibitor, BI-3406, broadly inhibits proximal RTK signaling will greatly expand the efficacy of therapies used to treat RTK/RAS-mutated cancers.
Topics & Concepts
Cancer researchChemistryOncogeneSignal transductionGeneMedicineBiochemistryCell cycleSignaling Pathways in DiseaseProtein Degradation and InhibitorsUbiquitin and proteasome pathways